BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was CHF 1.26 million compared to CHF 187.17 million a year ago. Net loss was CHF 322.65 million compared to net income of CHF 141.1 million a year ago. Basic loss per share from continuing operations was CHF 5.86 compared to basic earnings per share from continuing operations of CHF 2.55 a year ago. Diluted loss per share from continuing operations was CHF 5.86 compared to diluted earnings per share from continuing operations of CHF 2.55 a year ago.